Hideo Baba

Active 1988–2025

340
Papers
36,605
Citations
108
h-index
329
i10-index

Citations

Citations per year for Hideo Baba1989: 2 citations1990: 4 citations1991: 3 citations1992: 6 citations1993: 2 citations1994: 4 citations1995: 10 citations1996: 13 citations1997: 10 citations1998: 11 citations1999: 13 citations2000: 30 citations2001: 25 citations2002: 36 citations2003: 42 citations2004: 29 citations2005: 28 citations2006: 29 citations2007: 53 citations2008: 56 citations2009: 72 citations2010: 89 citations2011: 94 citations2012: 109 citations2013: 175 citations2014: 164 citations2015: 219 citations2016: 298 citations2017: 334 citations2018: 338 citations2019: 1,377 citations2020: 1,779 citations2021: 1,861 citations2022: 1,579 citations2023: 1,291 citations2024: 2,034 citations2025: 933 citations2026: 32 citations

Citation sources

Countries

World map of the countries and regions citing this authorChina: 3,982 citing papers, 23.7% of this breakdownUnited States: 2,994 citing papers, 17.8% of this breakdownJapan: 1,985 citing papers, 11.8% of this breakdownItaly: 715 citing papers, 4.2% of this breakdownGermany: 643 citing papers, 3.8% of this breakdownUnited Kingdom: 635 citing papers, 3.8% of this breakdownSouth Korea: 498 citing papers, 3% of this breakdownFrance: 433 citing papers, 2.6% of this breakdownSpain: 350 citing papers, 2.1% of this breakdownCanada: 342 citing papers, 2% of this breakdownNetherlands: 310 citing papers, 1.8% of this breakdownIndia: 282 citing papers, 1.7% of this breakdown
0%23.7%Other 21.7%

Fields

  • Medicine60.2%
  • Biochemistry, Genetics and Molecular Biology29.3%
  • Immunology and Microbiology6.1%
  • Dentistry0.8%
  • Neuroscience0.8%
  • Engineering0.7%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers4.4%
  • Gastric Cancer Management and Outcomes3.3%
  • Pancreatic and Hepatic Oncology Research3.1%
  • Esophageal Cancer Research and Treatment2.6%
  • Gut microbiota and health2.5%
  • Nutrition and Health in Aging2.3%
  • Other81.8%

Coauthors

All papers

Open in search
  1. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

    Authors: , , , , , , , , - Cancer Treatment Reviews 2017 cited by 1,642

  2. Fusobacterium nucleatumin colorectal carcinoma tissue and patient prognosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2015 cited by 1,074

  3. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316

  4. Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis

    Authors: , , , , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 455

  5. CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2011 cited by 1,187

  6. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2021 cited by 157

  7. Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer

    Authors: , , , , , , , , , - Annals of Surgery 2018 cited by 394

  8. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment

    Authors: , , , , , , , - Oncogene 2019 cited by 351

  9. Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma

    Authors: , , , , , , , , - Clinical Cancer Research 2019 cited by 199

  10. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2020 cited by 129

  11. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lynnette Marie Sholl, Ewa Sicińska, Jacob Sands, Scott J. Rodig, Kwok‐Kin Wong, Cloud P. Paweletz, Hideo Watanabe, David A. Barbie - Nature Medicine 2018 cited by 317

  12. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JCI Insight 2023 cited by 96

  13. Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Hepato-Biliary-Pancreatic Sciences 2022 cited by 237

  14. Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marios Giannakis, Shuji Ogino - Gastroenterology 2022 cited by 109

  15. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takehito Otsubo, Shin Ishihara, Takeshi Takahara, Mitsuo Shimada, Michiaki Unno, M Imamura, Nobuhiro Ohkochi, Yoshiaki Murakami, Jiro Fujimoto, Shinichi Ikuta, Y Fujino, Minoru Uebayashi, Shuichi Ishiyama, Norihisa Takakura, Yusuke Kumamoto, Takehito Kato, Isaku Yoshioka, Shinji Üemoto, Katsuhiko Yanaga - British journal of surgery 2018 cited by 395

  16. Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Research 2020 cited by 154

  17. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway

    Authors: , , , , , , , , , , , , , , , - Cancer Letters 2022 cited by 109

  18. Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2022 cited by 97

  19. B cell and B cell-related pathways for novel cancer treatments

    Authors: , , , , , , , , , - Cancer Treatment Reviews 2018 cited by 262

  20. Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis

    Authors: , , , , , , , , , , , , , , , , - Cancer Science 2021 cited by 75

  21. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 193

  22. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer

    Authors: , , , , , , , , , - Molecular Cancer 2022 cited by 122

  23. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kazuhiko Koike, Masahiro Kobayashi, Takaaki Higashi, Shigeki Nakagawa, Yo‐ichi Yamashita, Toru Beppu, Hideo Baba, Hiromitsu Kumada, Kazuaki Chayama, Thomas F. Baumert, Yujin Hoshida - Science Translational Medicine 2022 cited by 115

  24. Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells

    Authors: , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2017 cited by 241